Tag Archives: MBOT

Best Clean Energy Stocks To Buy For 2018

Natural gas for transportation leader Clean Energy Fuels Corp (NASDAQ:CLNE) has steadily grown and improved the quality of its business and business results over the past several years. Today’s Clean Energy Fuels is leaner, has a stronger balance sheet, and is in a solid position as a market leader in a growth industry.

But is the stock undervalued? By one metric, book value per share, it looks downright cheap. But management used a massive amount of stock to make ends meet over the past 18 months, destroying a significant amount of shareholder value in the process. Still, the loss of an important tax credit will have multimillion-dollar implications, and the sale of a very profitable part of the business raises questions about the company’s ability to generate positive cash flows this year.

Image source: Getty Images.

Best Clean Energy Stocks To Buy For 2018: Microbot Medical Inc. (MBOT)

Advisors’ Opinion:

  • [By Lisa Levin]

    Microbot Medical Inc (NASDAQ: MBOT) shares shot up 51 percent to $7.76 after reporting a significant technology patent allowance in the U.S. The patent allowance covers a device for the prevention of shunt stenosis.

  • [By Lisa Levin]

    Microbot Medical Inc (NASDAQ: MBOT) shares dropped 34 percent to $2.50. Microbot Medical reported a $10 million registered direct offering

    Shares of NewLink Genetics Corp (NASDAQ: NLNK) were down 12 percent to $11.13 after the company reported that indoximod + PROVENGE resulted in statistically significant improvement in rPFS for patients with mCRPC in Phase 2 trial.

  • [By Lisa Levin]

    Shares of Microbot Medical Inc (NASDAQ: MBOT) got a boost, shooting up 15 percent to $8.77 after the company reported a 700,000 share direct offering for $3.5 million.

Best Clean Energy Stocks To Buy For 2018: InterXion Holding N.V.(INXN)

Advisors’ Opinion:

  • [By Stephan Byrd]

    Interxion (NYSE:INXN) had its price objective boosted by Citigroup from $68.00 to $75.00 in a research note issued to investors on Friday morning. Citigroup currently has a buy rating on the technology company’s stock.

Best Clean Energy Stocks To Buy For 2018: Nuance Communications Inc.(NUAN)

Advisors’ Opinion:

  • [By Craig Jones]

    On CNBC's "Fast Money Halftime Report", Pete Najarian spoke about unusually high options activity in Nuance Communications Inc. (NASDAQ: NUAN).

  • [By Craig Jones]

    On CNBC's Fast Money Halftime Report, Jon Najarian spoke about high options activity in Nuance Communications Inc. (NASDAQ: NUAN). Traders were buying the June 19 calls for $1. The trade breaks even at $20 or 2.20 percent above the closing price on Wednesday. Najarian followed the trade and he is going to hold the position for two weeks.

  • [By Lisa Levin]

    Shares of Nuance Communications Inc. (NASDAQ: NUAN) got a boost, shooting up 10 percent to $17.05 after the company posted better-than-expected Q4 earnings. Raymond James upgraded Nuance Communications from Outperform to Strong Buy.

Best Clean Energy Stocks To Buy For 2018: ConAgra Foods, Inc.(CAG)

Advisors’ Opinion:

  • [By Laurie Kulikowski]

    Looking at where the stock is today compared to one year ago, we find that it is not only higher, but it has also clearly outperformed the rise in the S&P 500 over the same period. Although other factors naturally played a role, the company’s strong earnings growth was key. Looking ahead, our view is that this company’s fundamentals will not have much impact in either direction, allowing the stock to generally move up or down based on the push and pull of the broad market.

     

  • [By Lisa Levin]

    Conagra Brands Inc (NYSE: CAG) reported stronger-than-expected earnings for its third quarter.

    Conagra reported Q3 earnings of $0.48 per share on revenue of $1.98 billion. Analysts were expecting earnings of $0.44 per share on revenue of $1.98 billion.

  • [By Chris Lange]

    Conagra Brands Inc. (NYSE: CAG) is expected to release its most recent quarterly report early Thursday. The consensus forecast calls for $0.55 in EPS on $2.0 billion in revenue. Shares closed at $36.61 on Friday. The consensus target price is $42.21, and shares have changed hands between $32.16 and $41.63 in the past year.

  • [By Lisa Levin] Related SOFO 12 Biggest Mid-Day Losers For Tuesday Earnings Scheduled For December 10, 2015
    Related WSCI 15 Biggest Mid-Day Losers For Wednesday Earnings Scheduled For June 21, 2016 Companies Reporting Before The Bell
    Rite Aid Corporation (NYSE: RAD) is projected to report its quarterly earnings at $0.04 per share on revenue of $8.23 billion.
    Conagra Brands Inc (NYSE: CAG) is estimated to report its quarterly earnings at $0.45 per share on revenue of $2.11 billion.
    Bioanalytical Systems, Inc. (NASDAQ: BASI) is expected to report earnings for the fourth quarter.

     

  • [By Max Byerly]

    Change (CURRENCY:CAG) traded up 8.4% against the U.S. dollar during the twenty-four hour period ending at 21:00 PM Eastern on April 20th. One Change token can now be purchased for approximately $0.21 or 0.00002362 BTC on popular cryptocurrency exchanges including EtherDelta and Kucoin. Change has a total market cap of $7.72 million and approximately $56,746.00 worth of Change was traded on exchanges in the last day. In the last seven days, Change has traded up 26.7% against the U.S. dollar.

Best Clean Energy Stocks To Buy For 2018: American Woodmark Corporation(AMWD)

Advisors’ Opinion:

  • [By Lisa Levin]

    American Woodmark Corporation (NASDAQ: AMWD) shares shot up 25 percent to $124.80. American Woodmark reported purchase of RSI Home Products for $1.075 billion in enterprise value and posted upbeat quarterly earnings.

  • [By Lisa Levin]

    American Woodmark Corporation (NASDAQ: AMWD) shares shot up 29 percent to $128.15. American Woodmark reported purchase of RSI Home Products for $1.075 billion in enterprise value and posted upbeat quarterly earnings.

  • [By Lisa Levin]

    American Woodmark Corporation (NASDAQ: AMWD) was down, falling around 17 percent to $66.88 as the company reported weaker-than-expected quarterly earnings.

  • [By Lisa Levin]

    American Woodmark Corporation (NASDAQ: AMWD) was down, falling around 13 percent to $70.39 as the company reported weaker-than-expected quarterly earnings.

Top 5 High Tech Stocks To Buy For 2019

Executive Summary

Since 2009, Skyworks Solutions (NASDAQ:SWKS) has outperformed major equity-market benchmarks by a wide margin. Over a period of seven years ending in mid-2015, the stock rallied from $3.5 to $113. However, after June 2015, the upward trend reversed and a price drop of approximately 50% followed in a period of a wide stock market correction. Over the same period, (adjusted) revenue rose from $0.860 billion (FY 2008) to $3.289 billion (FY 2016). Adjusted earnings per share increased almost tenfold from $0.57 to $4.93. As of Friday December 23, 2016, the stock price is at $78.03.

Click to enlarge

Top 5 High Tech Stocks To Buy For 2019: Microbot Medical Inc. (MBOT)

Advisors’ Opinion:

  • [By Lisa Levin]

    Microbot Medical Inc (NASDAQ: MBOT) shares dropped 34 percent to $2.50. Microbot Medical reported a $10 million registered direct offering

    Shares of NewLink Genetics Corp (NASDAQ: NLNK) were down 12 percent to $11.13 after the company reported that indoximod + PROVENGE resulted in statistically significant improvement in rPFS for patients with mCRPC in Phase 2 trial.

  • [By Lisa Levin]

    Shares of Microbot Medical Inc (NASDAQ: MBOT) got a boost, shooting up 15 percent to $8.77 after the company reported a 700,000 share direct offering for $3.5 million.

  • [By Lisa Levin]

    Microbot Medical Inc (NASDAQ: MBOT) shares shot up 51 percent to $7.76 after reporting a significant technology patent allowance in the U.S. The patent allowance covers a device for the prevention of shunt stenosis.

Top 5 High Tech Stocks To Buy For 2019: Wins Finance Holdings Inc.(WINS)

Advisors’ Opinion:

  • [By Lisa Levin]

    Friday afternoon, the financial sector proved to be a source of strength for the market. Leading the sector was strength from Wins Finance Holdings Inc (NASDAQ: WINS) and Old Second Bancorp Inc. (NASDAQ: OSBC).

  • [By Lisa Levin]

    On Friday, the financial sector proved to be a source of strength for the market. Leading the sector was strength from Wins Finance Holdings Inc (NASDAQ: WINS) and Navient Corp (NASDAQ: NAVI).

Top 5 High Tech Stocks To Buy For 2019: AmerisourceBergen Corporation (Holding Co)(ABC)

Advisors’ Opinion:

  • [By Logan Wallace]

    AmerisourceBergen (NYSE: ABC) and Trxade Group (OTCMKTS:TRXD) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, dividends, earnings, institutional ownership and profitability.

  • [By Ethan Ryder]

    Alphabit (CURRENCY:ABC) traded down 14.2% against the US dollar during the 24-hour period ending at 19:00 PM Eastern on April 11th. Alphabit has a market cap of $0.00 and approximately $999.00 worth of Alphabit was traded on exchanges in the last 24 hours. One Alphabit token can now be purchased for about $33.91 or 0.00489408 BTC on cryptocurrency exchanges including C-CEX and Cryptopia. In the last week, Alphabit has traded up 2.4% against the US dollar.

  • [By Ben Levisohn]

    AmerisourceBergen (ABC) sprinted to the top of the S&P 500 after releasing Street-beating earnings this morning.

    Getty Images

    Shares of AmerisourceBergen jumped 8.8% to $$75.96 today, while the S&P 500 dropped fell 0.7% to 2,097.94.

    Leerink’s David Larsen and Matt Dellelo traces today’s big gain to Amerisource’s big drop following McKesson’s (MCK) earnings last week:

    This morningAmerisourceBergen reported adjusted EPS of $1.30, which was well ahead of Leerink/consensus of $1.22/$1.22. The quality of the beat appears decent, with some pressure in gross margin, completely offset by lower SG&A costs. Given the dramatic reduction in guidance provided byMcKesson (MP), investors had been very cautious heading into the quarter. We are pleased to see that F2017 EPS guidance of $5.63-$5.88 brackets Leerink/consensus estimates of $5.85/$5.82. Brand inflation is now expected to be in the +7-9% range from 10% previously, and F2017 is expected to be back-half loaded. Our first impression of the quarter is that the print and guide are good and there will likely be a relief rally in the shares.

    AmerisourceBergen’s market capitalization rose to $18.1 billion from $16.6 billion yesterday.

Top 5 High Tech Stocks To Buy For 2019: Simulations Plus, Inc.(SLP)

Advisors’ Opinion:

  • [By Lisa Levin]

    In trading on Friday, healthcare shares fell by 0.88 percent. Meanwhile, top losers in the sector included Simulations Plus, Inc. (NASDAQ: SLP), down 7 percent, and ZIOPHARM Oncology Inc. (NASDAQ: ZIOP), down 7 percent.

  • [By Stephan Byrd]

    Simulations Plus (NASDAQ:SLP) shares hit a new 52-week high and low during mid-day trading on Monday . The company traded as low as $18.55 and last traded at $18.35, with a volume of 49668 shares changing hands. The stock had previously closed at $18.20.

Top 5 High Tech Stocks To Buy For 2019: Shire plc(SHPG)

Advisors’ Opinion:

  • [By Ben Levisohn]

    We highlight the key takeaways below, which have read-throughs for brand drug companies we cover such asAllergan (AGN), Shire (SHPG), Valeant Pharmaceuticals International, Mallinckrodt,Endo International and Jazz Pharmaceuticals (JAZZ), among others.

  • [By Jim Robertson]

    That’s why its worth pointing out that just yesterday, small cap cannabinoid prodrug pharmaceutical stock Vitality Biopharma, Inc. (OTCQB: VBIO) announced the appointment of Tracy Rockney, J.D. to the position of Senior Regulatory Advisor. In addition to being the Co-Founder & Chief Operating Officer of OneSource Regulatory, a regulatory consulting firm, Rockney was previously:

    From May 2010 to May 2015, she was the VP, Regulatory Affairs at AbbVie Inc (NYSE: ABBV) leading the executive functions related to regulatory policy and intelligence. From August 1993 to January 2005, she held positions of increasing responsibility with Pfizer Inc (NYSE: PFE), formerly Wyeth.  From January 2005 to April 2010, she held positions with Shire PLC (NASDAQ: SHPG), including serving as Senior Director, Regulatory Affairs. This included responsibilities as Therapeutic Area Head for Shire’s Gastrointestinal Business Unit, Regulatory Advertising & Promotion and CMC. Rockney led the regulatory team and negotiations with the FDA for LIALDA which are part of the drug class of aminosalicylates that are now part of the clinical standard-of-care for treating inflammatory bowel disease. LIALDA™ was found to be effective in Phase 3 trials for inducing remission of active mild-to-moderate ulcerative colitis after eight weeks of treatment. LIALDA™ (also now marketed as Mezavant®) had 2016 U.S. sales of $714 million – up 16% relative to 2015 sales.

    Rockney’s work for Shire is of particular interest to Vitality Biopharma which has developed a new class of cannabinoid prodrugs (medications or compounds that, after administration, are converted within the body into a pharmacologically active drug), known as cannabosides, which upon ingestion can enable the selective delivery of THC and cannabidiol (CBD) to the gastrointestinal tract. Cannabosides could provide therapeutic benefits for infl

  • [By Todd Campbell]

    Takeda Pharmaceutical Co. (NASDAQOTH:TKPYY) announced late last month its interest in making an offer to acquire Shire (NASDAQ:SHPG), and according to Shire, Takeda has followed through with three separate bids. So far, Shire’s board of directors has rejected the offers as inadequate, but that doesn’t mean another offer won’t convince them otherwise. It’s unclear if Takeda will make yet another bid, or when it might do so. But even if it doesn’t, a deal could still be struck.

  • [By Benzinga News Desk]

    Takeda Pharmaceutical Co. on Tuesday reached an agreement to buy Shire PLC (NASDAQ: SHPG), capping a months long battle for control of the European drugmaker and marking the biggest-ever overseas acquisition by a Japanese company: Link $

  • [By Benzinga News Desk]

    Takeda Pharmaceutical Co. moved closer to securing a $64 billion takeover of Shire PLC (NASDAQ: SHPG) after the target said it was willing to recommend that shareholders accept the Japanese firm’s latest proposal and extended a deadline to reach a definitive agreement: Link $

best stock for investment

When John Milligan speaks, people listen — especially if they’re Gilead Sciences (NASDAQ:GILD) shareholders.

The big biotech’s CEO and its CFO Robin Washington sat down to field questions at the RBC Capital Markets 2017 Healthcare Conference in New York City on Wednesday. Milligan spoke directly to some of the most pressing concerns for Gilead shareholders. Here are three things he said that you’ll definitely want to know.

Image source: Getty Images.

1. We don’t know when the HCV business will bottom out.

The biggest worry on the minds of Gilead shareholders relates to the plunging sales for the biotech’s hepatitis C virus (HCV) franchise. John Milligan couldn’t — and didn’t — give any reason to think that there was a light at the end of the tunnel.

Milligan stated that Gilead doesn’t know if the HCV business will stabilize yet, and added that the company “might not know until it happens.” He said that his team initially thought that things might have stabilized last year, but “the dynamic didn’t play out as expected.”

best stock for investment: Iridium Communications Inc(IRDM)

Advisors’ Opinion:

  • [By Peter Graham]

    Small cap satellite stock Iridium Communications (NASDAQ: IRDM) reportedQ2 2017 earnings before the market opened on Thursday with results beating expectations. Total revenueincreased 2% to $111.6 million which consisted of $86.6 million of service revenue and $25.0 million of revenue related to equipment sales and engineering and support projects.Service revenue, which represents primarily recurring revenue from Iridium’s growing subscriber base, grew 4% and was 78% of total revenue. The Company ended the quarter with 913,000 total billable subscribers, which compares to 823,000 for the year-ago period and is up from 869,000 for the quarter ended March 31, 2017.Total billable subscribers grew 11% year-over-year, driven by growth in M2M and government customers. Net income was $24.8 million versus $26.9 million for the second quarter of 2016. The CEO commented:

  • [By Jim Robertson]

    Trump’s proposal to spin off air traffic control from the Federal Aviation Administration (FAA) bodes well for small cap satellite stock Iridium Communications (NASDAQ: IRDM), but theres a bigger opportunity for the Company in theInternet of Things (IoT) space. Technology company Harris Corporation (NYSE: HRS) is already a leading candidate to supply the FAA with real-time aircraft tracking data in partnership with Iridium Communications with the latter having a joint venture that has partnered with air traffic control authorities in Canada, Italy, Ireland and Denmark to provide air traffic surveillance (in cooperation with Harris).

best stock for investment: Microbot Medical Inc. (MBOT)

Advisors’ Opinion:

  • [By Lisa Levin]

    Microbot Medical Inc (NASDAQ: MBOT) shares shot up 51 percent to $7.76 after reporting a significant technology patent allowance in the U.S. The patent allowance covers a device for the prevention of shunt stenosis.

  • [By Lisa Levin]

    Shares of Microbot Medical Inc (NASDAQ: MBOT) got a boost, shooting up 15 percent to $8.77 after the company reported a 700,000 share direct offering for $3.5 million.

  • [By Lisa Levin]

    Microbot Medical Inc (NASDAQ: MBOT) shares dropped 34 percent to $2.50. Microbot Medical reported a $10 million registered direct offering

    Shares of NewLink Genetics Corp (NASDAQ: NLNK) were down 12 percent to $11.13 after the company reported that indoximod + PROVENGE resulted in statistically significant improvement in rPFS for patients with mCRPC in Phase 2 trial.

best stock for investment: E*TRADE Financial Corporation(ETFC)

Advisors’ Opinion:

  • [By Dan Caplinger]

    Meanwhile, E*Trade (NASDAQ:ETFC) decided to split the difference. Effective March 13, E*Trade’s commission structure will get split in two. Base rate customers will see their commissions fall from $9.99 to $6.95 per trade, matching TD Ameritrade. However, E*Trade created a new structure for active traders, defined as those who execute 30 or more trades every three months. For those customers, E*Trade will have $4.95 per trade commissions, and options charges will fall by a third, to $0.50 per contract. CEO Karl Roessner said that although “an exceptional customer experience is far more important to traders and investors than price, with our new commission structure, we are able to reward our most active equity and derivative traders and investors.”

  • [By Jon C. Ogg]

    E*Trade Financial Corp. (NASDAQ: ETFC) was up another 1.6% at $32.97. Ithas a total market cap of $9 billion, and over the past five trading days the stock has gained 17%. Shares of Morgan Stanley (NYSE: MS) were last seen at $39.09, up 17% in the past fivetrading days. The market cap is$74.7 billion.

  • [By Chris Neiger]

    This article will walk your through all the steps for setting up an individual E*TRADE (NASDAQ:ETFC) brokerage account, which should only take about five to 10 minutes to complete. If you want to compare offers from other brokers, or view their features, check out ourbroker comparison page.

  • [By David Zeiler]

    In just three years, Robinhood’s customer base has surpassed that of entrenched online brokerage E*Trade Financial Corp. (Nasdaq: ETFC), which spent 35 years accumulating 3.6 million customers.

best stock for investment: Xenon Pharmaceuticals Inc.(XENE)

Advisors’ Opinion:

  • [By Jim Robertson]

    Yesterday, our Under the Radar Moversnewsletter suggested going long on small cap biopharmaceutical stock Xenon Pharmaceuticals Inc (NASDAQ: XENE):

  • [By Lisa Levin]

    Xenon Pharmaceuticals Inc (NASDAQ: XENE) shares dropped 51 percent to $4.80 after the company disclosed that XEN801 did not meet efficacy endpoints in Phase 2 trial.

  • [By Lisa Levin]

    Xenon Pharmaceuticals Inc (NASDAQ: XENE) shares dropped 53 percent to $4.68 after the company disclosed that XEN801 did not meet efficacy endpoints in Phase 2 trial.

best stock for investment: DBV Technologies S.A.(DBVT)

Advisors’ Opinion:

  • [By Lisa Levin]

     

    Losers
    DBV Technologies SA – ADR (NASDAQ: DBVT) shares tumbled 50.6 percent to $23.73 after the company disclosed that its peanut allergy trial failed to meet primary endpoint.
    Connecture Inc (NASDAQ: CNXR) shares declined 40.8 percent to $0.290. Connecture reported that it will voluntarily delist from the NASDAQ for OTCQX Market.
    Walter Investment Management Corp (NYSE: WAC) slipped 19.2 percent to $0.410. On Friday, Walter Investment Management disclosed that it has reached an agreement with term lenders and senior noteholders on financial restructuring.
    Eldorado Gold Corp (USA) (NYSE: EGO) shares dropped 15.9 percent to $1.83. Eldorado Gold lowered its production guidance for its Kisladag operation.
    Seanergy Maritime Holdings Corp. (NASDAQ: SHIP) shares fell 15.4 percent to $1.04.
    Future Fintech Group Inc (NASDAQ: FTFT) dropped 13.6 percent to $1.53. Future FinTech reported filing of proxy statement, including proposal for corporate restructuring.
    Concordia International Corp (NASDAQ: CXRX) shares fell 12.3 percent to $0.500 after dipping 38.71 percent on Friday.
    Aemetis Inc (NASDAQ: AMTX) shares declined 11.3 percent to $0.550
    OncoSec Medical Inc (NASDAQ: ONCS) dipped 10.5 percent to $1.12. OncoSec reported a $7.1 million registered direct at-the-market offering at a price of $1.34375 per share.
    Evoke Pharma Inc (NASDAQ: EVOK) shares fell 10.35 percent to $3.08 after the company disclosed 'positive' topline results from comparative exposure pharmacokinetic study for Gimoti.
    Eiger Biopharmaceuticals Inc (NASDAQ: EIGR) shares dropped 9.4 percent to $11.60 as the company disclosed Phase 2 interim 24-week data with pegylated interferon lambda in Hepatitis Delta Virus infection at the American Association for the Study of Liver Diseases Meeting.
    Viking Therapeutics Inc (NASDAQ: VKTX) shares slipped 6.6 percent to $2.80. Viking Therapeutics presented results from proof-of-concept study of VK0214 in in vivo

  • [By Monica Gerson]

    DBV Technologies SA ADR (NASDAQ: DBVT) is expected to post a quarterly loss at $0.60 per share.

    Northern Technologies International Corp (NASDAQ: NTIC) is projected to post its quarterly earnings.

  • [By Paul Ausick]

    DBV Technologies SA (NASDAQ: DBVT) dropped about 53.5% Monday to post a new 52-week low of $22.33 after closing at $48.07 on Friday. The stock’s 52-week high is $50.57. Volume of around 12 million was about 60 times the daily average. The French drug maker’s peanut allergy treatment failed a phase 3 study.

best stock for investment: Corbus Pharmaceuticals Holdings, Inc.(CRBP)

Advisors’ Opinion:

  • [By Sean Williams]

    This rapid growth in legal pot has create quite the demand for marijuana stocks. The seven largest marijuana stocks by market cap have all put on a show over the past couple of years. Here are those seven “green giants” listed with their market caps as of March 17, 2017, along with their trailing one-year total returns.

    GW Pharmaceuticals (NASDAQ:GWPH): $3.0 billion, up 64% Canopy Growth Corp. (NASDAQOTH:TWMJF): $904 million, up 259% Aphria (NASDAQOTH:APHQF) $440 million, up 381% Aurora Cannabis (NASDAQOTH:ACBFF): $482 million, up 299% AXIM Biotechnologies (NASDAQOTH:AXIM): $562 million, up 1,720% Corbus Pharmaceuticals (NASDAQ:CRBP): $450 million, up 431% Medical Marijuana (NASDAQOTH:MJNA): $221 million, up 254%

    As you can see, these are some hefty valuations — and some exceptionally strong moves higher on the heels of marijuana’s expansion. With the exception of GW Pharmaceuticals, every one of the largest marijuana stocks has at least tripled in value over the trailing 12 months, with cannabinoid-based drug developer AXIM Biotechnologies skyrocketing more than 1,700%!

  • [By Keith Speights]

    Corbus Pharmaceuticals (NASDAQ:CRBP) managed to become one of the top-performing biotech stocks on the market in 2016. Over the last 12 months, Corbus’ share price has soared 550%.